PDX INSIGHTS
PIONEERING CANCER RESEARCH
Model Details

Patient Information for Model: TCCC-OS32

Model Contact
Model: TCCC-OS32
Model Contact: Nino Rainusso
Institution: TCH Sarcoma PDX Program
Email: ncrainuss@texaschildrens.org

Patient Information
Clinical Timeline


Clinical Information at Collection
Clinical Biomarkers/Mutations
Pathology Information at Collection

Model Information for Model: TCCC-OS32

Model Details - Initial Implantation of Patient Tissue
Mutations (Cancer Gene Census List)
Mutation data is currently not available.

CNV
There are no omics data for this model.


Histology Information for Model: TCCC-OS32
There are no histology images for this model.













Metastasis Information for Model: TCCC-OS32
 
Patient
PDX
Bone
Lung

Patient Treatment Information for Model: TCCC-OS32

Event IdTreatmentTreatment SettingAge at StartAge at EndDurationClinical ResponsePathologic ResponseReason Stopped
10Methotrexate, Doxorubicin, CisplatinNeoadjuvant14.514.7591 daysPartial responsePoor response (40% tumor necrosis) Surgical resection (local control)
20Methotrexate, Doxorubicin, CisplatinAdjuvant14.7514.9158 daysPartial responseSurgical resection (metastectomy)
30Ifosfamide /EtoposideAdjuvant14.9115.0862 daysNo evidence of diseaseEnd of therapy
40Investigational agent /PalliativeAdjuvant15.3315.4129 days













Please wait...